New effective, field-adapted drug. Together with Bayer Pharma, we are working to develop emodepside as a new treatment for river blindness with the potential to kill both adult filarial worms and their embryonic larvae, which can cause debilitating and disfiguring clinical symptoms.

A potential new oral treatment for visceral leishmaniasis. DNDi and Novartis initiated a collaboration and licence agreement to jointly develop LXE408 – a first-in-class compound, discovered at Novartis with financial support from Wellcome.

DNDi and our partners are prioritizing drug development for dengue with a focus on pregnant women, young children, and people with comorbidities. In the short term, we are working to repurpose existing direct-acting antivirals and host-directed therapies. Our aim over the medium term is to develop all-new antivirals.